Abbott India Ltd. (BSE: 500488) is a Mumbai, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹56,531 Cr, it ranks #190 by market cap among the 6,197 Indian listed companies on FinBizNet, and #1 of 63 in Pharmaceuticals. At ₹26,430.00 (as of 16 Nov 2026), the share price is 13.8% below its 52-week high of ₹30,655.00 and 7.2% above its 52-week low of ₹24,650.00. The share price is down 8.1% over one year and down 4.3% over three months.
| Current Price | ₹26,430.00 |
|---|---|
| Market Cap | ₹56,531 Cr |
| BSE Code | 500488 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 36.3 |
| Return on Equity | 34.46% |
| Return on Assets | 18.28% |
| 52-Week Range | ₹24,650.00 – ₹30,655.00 |
| 1-Year Price Change | -8.1% |
| 3-Month Price Change | -4.3% |
| Beta (1Y) | -0.17 |
| Dividend Yield | 1.98% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.abbott.co.in |
| Revenue | ₹1,814 Cr |
|---|---|
| Net Profit | ₹429 Cr |
| Net Margin | 23.6% |
| EPS (Basic) | ₹201.66 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Abbott India Ltd. reported revenue of ₹1,814 Cr in Q1 FY27, up 4.3% from ₹1,738 Cr in Q1 FY26 and up 6.1% from ₹1,710 Cr in Q4 FY26. It posted a net profit of ₹429 Cr for the quarter, against a net profit of ₹366 Cr in Q1 FY26 (up 17.1%). Across the 6 quarters from Q4 FY25 to Q1 FY27, quarterly revenue ranged from ₹1,605 Cr (Q4 FY25) to ₹1,814 Cr (Q1 FY27). The company was profitable in each of these 6 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q1 FY27 | ₹1,814 Cr | ₹429 Cr | 23.6% |
| Q4 FY26 | ₹1,710 Cr | ₹395 Cr | 23.1% |
| Q3 FY26 | ₹1,724 Cr | ₹376 Cr | 21.8% |
| Q2 FY26 | ₹1,757 Cr | ₹415 Cr | 23.6% |
| Q1 FY26 | ₹1,738 Cr | ₹366 Cr | 21.0% |
| Q4 FY25 | ₹1,605 Cr | ₹367 Cr | 22.9% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 74.99% of Abbott India Ltd.'s shares as of Dec 2018, unchanged from Sept 2017. Delivery averaged 55.0% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women’s health, metabolic, central nervous system, vaccines, and multispecialty, including insomnia, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto, GI & hepato, hormones, neuro-psychiat, pain management, respiratory, hepatic, neuroscience, metabolics, gennext, and consumer care products. The company was formerly known as Knoll Pharmaceuticals Limited and changed its name to Abbott India Limited in July 2002. The company was founded in 1910 and is headquartered in Mumbai, India. Abbott India Limited operates as a subsidiary of Abbott Capital India Limited.
1. Pharmaceuticals-This segment offers pharmaceutical products. It provides products and solutions across various therapeutic areas, such as women's health, gastroenterology, central nervous system, metabolics, multi-specialty, vaccines, consumer health, etc.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Astrazeneca Pharma India Ltd. | ₹16,078 Cr | 85.9 | 22.82% | ₹729 Cr | -34.3% |
Listed by market capitalisation. Ratios are shown for context only.
Abbott India Ltd. is trading at ₹26,430.00, with a market capitalisation of ₹56,531 Cr.
Abbott India Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Abbott India Ltd. has a P/E of 36.3 and a return on equity of 34.46%.
Abbott India Ltd. is listed on the BSE under the scrip code 500488.
Abbott India Ltd.'s share price is down 8.1% over one year and down 4.3% over three months. Its 52-week range is ₹24,650.00 to ₹30,655.00.
In Q1 FY27, Abbott India Ltd. reported revenue of ₹1,814 Cr and net profit of ₹429 Cr, with basic EPS of ₹201.66 (standalone, parsed from the company's exchange filing).
Abbott India Ltd. reported revenue of ₹1,814 Cr in Q1 FY27, up 4.3% from ₹1,738 Cr in Q1 FY26 and up 6.1% from ₹1,710 Cr in Q4 FY26.
Promoters held 74.99% of Abbott India Ltd.'s shares as of Dec 2018, unchanged from Sept 2017.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.